Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above

Condition:   Herpes Zoster Interventions:   Biological: Low dose Recombinant Herpes Zoster Vaccine (CHO cells);   Biological: High dose Recombinant Herpes Zoster Vaccine (CHO cells);   Biological: Positive control;   Biological: Placebo Sponsors:   MAXVAX Biotechnology Limited Liability Company;   Henan Center for Disease Control and Prevention Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials